Clinical trials: Semaglutide
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich
Semaglutide-Induced Gastric Motility, Anesthesia
Effect of Itopride on Semaglutide Gastroparesis
Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery.
- Trial name
- NCT07254715
- Testing
- Itopride HCI 50 mg
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Pediatric Obesity, Metabolic and Bariatric Surgery
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery).
- Conditions
- Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
- Trial name
- NCT06934655
- Testing
- Semaglutide 2.4 mg
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Los Angeles
Semaglutide-Induced Gastric Motility, Gastroparesis
Body Surface Gastric Mapping in Patients on Semaglutide
Glucagon-like receptor-1 agonists (GLP-1 RAs), such as Semaglutide (Ozempic), are a class of drugs used for glycemic control in diabetes, and for weight loss and management in obesity.
- Trial name
- NCT06401746
- Testing
- Gastric Alimetry
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- University of Western Sydney
Type 2 Diabetes, Obesity
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide.
- Conditions
- Type 2 Diabetes, Obesity, Semaglutide, GLP-1
- Trial name
- GLIMMER (NCT07272837)
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Type 2 Diabetes Mellitus (T2DM), Semaglutide
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
- Trial name
- NCT07272343
- Testing
- semaglutide, caloric restriction
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients, Obesity &Amp; Overweight
Coronary Flow Reserve Changes After Semaglutide Treatment
The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients.
- Trial name
- NCT07190144
- Where
- Turkey (Türkiye)
- Volunteers
- 122 people
- Sponsor
- Ekrem Bilal Karaayvaz
Obesity in Diabetes, Obesity/Therapy
Semaglutide Treatment in Type 1 Diabetes
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic…
- Conditions
- Obesity in Diabetes, Obesity/Therapy, Type 1 Diabetes Mellitus (T1DM), Insulin Sensitivity/Resistance
- Trial name
- OBES1TY (NCT06909006)
- Testing
- Semaglutide 2.4mg
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Nordsjaellands Hospital
PCOS (Polycystic Ovary Syndrome), Semaglutide
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
To investigate the efficacy of semaglutide in obese infertile women of childbearing age with polycystic ovary syndrome (PCOS), we design this prospective, randomized, open and controlled study.
- Trial name
- NCT05702905
- Testing
- Metformin Hydrochloride 500 MG, Semaglutide, 1.34 mg/mL, Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Peking University First Hospital
Scleroderma, Systemic, Fibrosis
Subcutaneous Semaglutide in Systemic Scleroderma
This trial will study the safety and efficacy of subcutaneous semaglutide for the treatment of Systemic Sclerosis
- Conditions
- Scleroderma, Systemic, Fibrosis, Semaglutide
- Trial name
- NCT06149260
- Testing
- Semaglutide Pen Injector
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Xiangya Hospital of Central South University
PCOS, Semaglutide
The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity
The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA) semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of neural response in central reward processing…
- Conditions
- PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome
- Trial name
- NCT04263415
- Testing
- Semaglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana